New Medical Guidelines Offer Clearer Path for Menopause Treatment

The American College of Obstetricians and Gynecologists (ACOG) has officially released updated guidelines for the treatment of menopause symptoms. This new guidance, which replaces the previous 2014 version, provides a clearer path for doctors to help patients manage issues like hot flashes, night sweats, and sleep problems. As reported by MedPage Today, these recommendations align with a growing agreement among medical experts that many women have been suffering in silence, and that effective treatments are currently underused.

According to NPR News, the update emphasizes that the safety of hormone replacement therapy (HRT) is now well-established for the right patients. For years, many women and doctors were hesitant to use hormone therapy due to older studies from 2002 that suggested potential health risks, such as heart disease or breast cancer. However, researchers have since revisited that data and found that those early studies had limitations, particularly because many participants were already over the age of 60. Modern research now provides a much clearer picture, allowing doctors to offer better-informed care.

For women who are good candidates for treatment, ACOG strongly recommends starting hormone therapy before age 60, or within 10 years of the start of natural menopause. Dr. Robert Kauffman, a co-author of the guidelines, noted during a press briefing that hormone therapy is likely the best option for newly menopausal women who are experiencing symptoms. For women who still have a uterus, the treatment typically involves a combination of estrogen and progestogen. Progestogen is included because estrogen alone can stimulate the growth of the uterine lining, which may increase the risk of endometrial cancer. For those who do not have a uterus, estrogen alone is often sufficient.

While hormone therapy is a primary recommendation, the new guidelines also highlight the importance of an individualized approach. Not every woman is a candidate for hormone therapy. According to ACOG, reasons to avoid it include a history of certain cancers, blood clots, stroke, heart attack, or liver disease. For these patients, the guidelines suggest alternative treatments. These include selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs), which are types of antidepressants that can help with both mood swings and hot flashes.

Furthermore, the medical community now has access to newer, non-hormonal options. NPR News reports that the Food and Drug Administration has recently approved medications such as fezolinetant and elinzanetant. These drugs work by blocking specific chemical messengers in the brain that manage body temperature and sleep cycles. Dr. Catherine Cansino, chair of ACOG’s Committee on Clinical Practice Guidelines, explained that these options are exciting because they were developed with a specific understanding of how the body regulates temperature and sleep. This gives doctors a broader range of tools to help patients find relief.

Dr. JoAnn E. Manson, a professor at Harvard Medical School, told MedPage Today that the timing of treatment is crucial. She noted that the new guidelines are very similar to those from other professional societies, which is a positive sign for patients. She explained that for too long, many women were discouraged from seeking help due to outdated fears. With these updated, evidence-based recommendations, the goal is to ensure that women receive the support they need during this natural transition.

Menopause affects approximately 2 million women in the United States each year, with the average age of onset being just under 50. However, symptoms often begin years before the final menstrual period. By providing these updated standards, ACOG hopes to move past the confusion of the last two decades. The new guidelines encourage open conversations between patients and doctors to determine the safest and most effective plan for each individual. As the medical field continues to study the long-term effects of these treatments, the focus remains on improving the quality of life for women experiencing these common, yet often difficult, symptoms.